Clinical Trial Update: Study of VELCADE and Rituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating Velcade (bortezomib) in combination with Rituximab for relapsed or refractory B-cell non-Hodgkin lymphoma has been completed, with re…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Non-hodgkin Lymphoma
• Non-hodgkin Lymphoma

Drugs mentioned

• Rituxan (rituximab)
• Velcade (bortezomib)

Snippet

Sponsor: Millennium Pharmaceuticals, Inc. | Conditions: Non-Hodgkin's Lymphoma | Phase 3 | Status: COMPLETED | Results posted: 2011-07-26